

# The Use of MRI in the Diagnosis of Early-Stage Breast Cancer

Turki Khulaif Alanazi<sup>1</sup>, Abdullah Naffaa Alsafari<sup>2</sup>, Abdulrahman Abdullah Alsudays<sup>3</sup>, Abdullah Hulayyil Saad Alenazi<sup>4</sup>, Mohammed Maashi Q Alanazi<sup>5</sup>, Ahmed Majid Alzahrani<sup>6</sup>, Mohammad Khulaife Alabdali<sup>4</sup>, Naif Salem Almouwallad<sup>7</sup>, Faris Owais Alharbi<sup>8</sup>

1. Radiology specialist, Public Health, Gurayat, Saudi Arabia
2. Medical physics specialist, Gurayat General Hospital, Gurayat, Saudi Arabia
3. Radiology Technologist, Prince Mutab Bin Abdulaziz hospital, Sakaka, Saudi Arabia
4. Radiology technician, Forensic Medicine, Gurayat, Saudi Arabia
5. Radiology technician, Gurayat Mental Health Hospital, Gurayat, Saudi Arabia
6. Medical physics specialist, Prince Mutab Bin Abdulaziz hospital - Sakaka, Saudi Arabia
7. Medical physics, King Abdulaziz hospital, Sakaka, Saudi Arabia
8. Senior Specialist of Radiological Technology, Prince Metaab Bin Abdulaziz Hospital, Aljouf, Saudi Arabia

## ABSTRACT

Magnetic Resonance Imaging (MRI) has emerged as a vital tool in the diagnosis of early-stage breast cancer, enhancing the detection and characterization of lesions that may not be visible through traditional mammography, particularly in dense breast tissue. MRI's high sensitivity allows it to identify small tumors and assess the extent of disease more accurately, which is crucial in determining the appropriate treatment plan. It is especially effective in women with a genetic predisposition to breast cancer or those with a strong family history, as it can detect multifocal or bilateral disease that may otherwise go unnoticed. Moreover, MRI plays a significant role in the monitoring of patients undergoing treatment and evaluating the response to neoadjuvant chemotherapy. By providing detailed imaging of tumor changes over time, clinicians can make informed decisions about surgical interventions and potential adjustments in therapy. As the technology continues to evolve, the integration of MRI into routine breast cancer screening protocols promises to further improve early detection outcomes, ultimately leading to better survival rates and quality of life for patients.

**KEYWORDS:** MRI, early-stage breast cancer, diagnosis, mammography, dense breast tissue, sensitivity, genetic predisposition, multifocal disease, bilateral disease, neoadjuvant chemotherapy, treatment monitoring, imaging technology, early detection, survival rates.

## 1. Introduction

Breast cancer remains one of the most prevalent forms of cancer affecting women globally, with significant implications for both public health and individual patients.

As of recent reports, breast cancer accounts for approximately 25% of all cancer diagnoses among women, leading to a heightened demand for effective diagnostic strategies that can identify the disease at its earliest stages. Early detection is paramount, as it is crucial for improving survival rates and treatment outcomes. In this context, advancements in imaging technologies have significantly transformed the landscape of breast cancer diagnosis. Among them, Magnetic Resonance Imaging (MRI) has emerged as a pivotal tool, often employed to complement traditional imaging modalities such as mammography and ultrasound [1].

MRI utilizes powerful magnets and radio waves to generate detailed images of the anatomical structures within the body, providing clear contrasts between various types of tissues. This capability makes MRI particularly beneficial for visualizing soft tissues, including the highly glandular composition of breast tissue. Unlike mammography, which primarily detects calcifications and masses, MRI offers enhanced sensitivity for detecting abnormal growths in dense breast tissues, which can hinder the effectiveness of standard mammographic techniques. Consequently, MRI has become an invaluable adjunct in the diagnostic arsenal for early-stage breast cancer, especially in high-risk populations [2].

The use of MRI in breast cancer diagnosis is supported by numerous studies that advocate for its efficacy in detecting smaller tumors that may not be visible through other modalities. For instance, a systematic review highlighted that breast MRI can detect 20-30% more cancers than mammography alone, particularly in patients with dense breast tissue or those with a genetic predisposition to breast cancer, such as BRCA1 and BRCA2 mutation carriers. In such instances, the ability of MRI to capture subtle changes in breast tissue morphology can facilitate timely interventions and potentially improve patient prognosis [3].

Moreover, MRI's capacity for functional imaging, through techniques like dynamic contrast-enhanced MRI (DCE-MRI), allows for the assessment of tumor characteristics such as vascularity and cellularity, which may influence therapeutic decisions. This functional analysis can further aid in differentiating between benign and malignant lesions, thereby reducing the frequency of unnecessary biopsies and associated patient anxiety. The integration of MRI into the diagnostic pathway not only enhances the accuracy of breast cancer detection but also aligns with a broader clinical objective—personalizing treatment strategies based on precise tumor assessments [4].

Despite its advantages, the application of MRI in early-stage breast cancer diagnosis is not without challenges. One significant limitation is the increasingly high false-positive rates, which can lead to overtreatment or further invasive diagnostics without conclusive evidence of malignancy. Such outcomes underline the necessity for careful patient selection and the implementation of MRI as part of a multidisciplinary approach rather than a standalone diagnostic tool. Moreover, logistical issues, including the availability of MRI facilities and the associated costs, pose barriers to widespread adoption, particularly in resource-limited settings [5].

As the healthcare landscape continues to evolve, there is a pressing need for further research that focuses on refining the clinical guidelines surrounding the use of MRI in breast cancer screening and diagnosis. Investigating the role of MRI in various

patient demographics, its cost-effectiveness relative to other imaging modalities, and the development of advanced imaging techniques are all vital areas for future exploration. By addressing these gaps, the medical community can leverage MRI's capabilities to facilitate earlier intervention, ultimately improving the outcomes for those affected by breast cancer [6].

### The Role of Imaging Techniques in Breast Cancer Detection:

Mammography is the most widely used imaging technique for breast cancer screening and diagnosis. This X-ray-based method has been proven effective in detecting breast tumors that may be too small to feel. Mammograms are typically recommended for women over 40, or earlier for those with increased risk factors, such as a family history of breast cancer. The primary strength of mammography lies in its ability to identify calcifications and masses, often indicating early-stage breast cancer [7].

One of the most significant advancements in mammography is the development of digital mammography, which allows for improved image storage and manipulation, facilitating better analysis. Furthermore, 3D mammography, or tomosynthesis, has emerged as a revolutionary improvement. This technique captures multiple images of the breast from various angles, allowing radiologists to examine the breast in slices, which enhances the detection of cancers in dense breast tissue and reduces false positives [8].

Despite its advantages, mammography does have limitations. It can sometimes miss tumors, particularly in women with dense breast tissue, which may obscure abnormalities in X-ray images. Moreover, the compression involved in the procedure can cause discomfort and may lead to anxiety related to false positives. As a result, supplementary imaging techniques are often employed, particularly in high-risk populations or for further evaluation of suspicious findings [8].

Breast ultrasound is another imaging technique that plays a pivotal role in breast cancer detection. It uses high-frequency sound waves to create images of the breast tissue. Unlike mammography, ultrasound is not typically used as a primary screening tool; however, it serves as an invaluable adjunct, particularly in certain circumstances [8].

Ultrasound is particularly beneficial for evaluating dense breast tissue, as it can provide clearer images when mammograms may fall short. It is also instrumental in distinguishing between solid masses and fluid-filled cysts, helping to determine the nature of a breast abnormality. For women with dense breasts or those who present with palpable masses, ultrasound can help guide biopsies by pinpointing areas of concern [9].

The key advantages of ultrasound include its safety—there is no exposure to ionizing radiation—and its ability to provide real-time imaging, making it useful for guiding minimally invasive procedures. Nevertheless, it is essential to note its limitations. Ultrasound is operator-dependent, where the skill and experience of the technician play significant roles in the quality and accuracy of the results. Additionally, it can produce false positives, leading to unnecessary biopsies and procedures [10].

Magnetic Resonance Imaging (MRI) is increasingly utilized in breast cancer detection, particularly for high-risk patients or those with an ambiguous mammogram or ultrasound result. MRI uses strong magnetic fields and radio waves to generate detailed images of the breast. This technique is especially valuable for identifying tumors that may be obscured in traditional imaging modalities [11].

One of the unique advantages of breast MRI is its ability to detect cancer with a higher sensitivity than mammography; studies indicate that it can identify breast tumors that are invisible on mammograms, particularly in women with dense breast tissue. MRI is also beneficial for evaluating the extent of the disease in patients already diagnosed with breast cancer, allowing for more informed treatment decisions [11].

However, the use of breast MRI is often limited by its cost, availability, and the need for contrast agents, which may lead to allergic reactions in some patients. Furthermore, while MRI's sensitivity is high, its specificity is lower than that of mammography, potentially leading to false positives that may require additional biopsies [12].

As technology continues to evolve, several innovative imaging techniques are being researched and integrated into breast cancer detection protocols. Emerging modalities such as Positron Emission Tomography (PET) imaging, Digital Breast Tomosynthesis (DBT), and breast-specific gamma imaging show promise in enhancing detection rates and providing more accurate assessments of breast health [13].

PET imaging, which detects metabolic activity in tissues, can be particularly useful for staging breast cancer and identifying distant metastasis. Similarly, breast-specific gamma imaging allows for the visualization of tumors with higher specificity, primarily used for women with dense breasts or at high risk [13].

Artificial Intelligence (AI) is also playing a transformative role in breast cancer imaging. Machine learning algorithms are being trained to analyze mammograms and other imaging results, aiding radiologists in improving accuracy, reducing reading times, and minimizing unnecessary biopsies. The integration of AI has the potential to revolutionize how breast cancer is detected and monitored, providing individualized approaches to patient care [14].

#### Principles and Technology Behind MRI:

Magnetic Resonance Imaging, commonly referred to as MRI, stands as one of the most valuable and sophisticated tools in modern medical diagnostics. The technology leverages the principles of nuclear magnetic resonance (NMR), a technique rooted in physics and chemistry, to generate detailed images of the internal structures of the body. Understanding the principles underlying MRI, alongside its technological components, reveals the intricacies that enable its wide-ranging applications in healthcare [15].

At the core of MRI technology is the manipulation of atomic nuclei in a magnetic field. The most abundant nucleus in the human body is that of hydrogen, which is plentiful due to the high water content in biological tissues. MRI exploits the

magnetic properties of hydrogen nuclei to produce highly detailed images [15].

When a patient is placed inside a strong magnetic field, typically ranging from 1.5 to 3.0 Tesla, the protons in hydrogen atoms align with the direction of the magnetic field. Although this alignment is ephemeral and typically random, the application of a specific radiofrequency (RF) pulse causes these protons to temporarily absorb energy and enter an excited state, where they are knocked out of alignment with the magnetic field [15].

Once the RF pulse is turned off, the protons begin to return to their original alignment, releasing the absorbed energy in the form of radio waves. This process, known as relaxation, occurs at distinct rates depending on the type of tissue. There are two primary types of relaxation measured in MRI: T1 (spin-lattice) relaxation, which involves energy transfer to the surrounding lattice or tissue; and T2 (spin-spin) relaxation, which refers to the decay of transverse magnetization caused by interactions between spins. It is this differential relaxation behavior among various tissues that allows MRI to generate contrast, providing images of anatomical and pathological structures [16].

## The Technological Components of MRI

The MRI scanner comprises several essential components that work synergistically to produce diagnostic images [17].

### 1. Magnet

The primary component of an MRI system is the magnet. The strength and homogeneity of the magnetic field are critical, as they influence the quality of the images produced. Superconducting magnets, which operate at very low temperatures to maintain their superconductivity, provide the highest field strengths and are common in clinical settings. The magnet's design ensures a uniform magnetic field; any variations can lead to image artifacts or distortions [17].

### 2. RF Coils

RF coils serve a dual purpose: they transmit the RF pulses that excite the protons and receive the radio waves emitted by the protons during relaxation. Different coils are designed to target specific body parts, such as the head, spine, or joints. Selecting the appropriate coil enhances the signal-to-noise ratio, improving image quality [17].

### 3. Gradient Magnets

In order to localize the area of interest within the body, gradient coils are employed. These coils create variations in the magnetic field strength, allowing spatial encoding of the signals emitted from the tissues. By altering the magnetic field in three dimensions, MRI can differentiate signals from various parts of the body, creating a comprehensive image of the region being examined [18].

### 4. Computer System

The computer system is pivotal to the functionality of MRI through image reconstruction and processing. Once the RF signals are collected, they are transformed from analog signals to digital data, which is then manipulated through

various algorithms to create the final image. Advanced software enables radiologists to adjust parameters such as contrast and resolution, allowing for optimal visualization of tissues, blood vessels, and even pathological conditions such as tumors or brain lesions [18].

### Clinical Applications of MRI

MRI has become indispensable in clinical practice due to its ability to provide detailed anatomical images without the use of ionizing radiation, as is the case with X-rays and computed tomography (CT) scans. Its applications span a myriad of medical fields, including neurology, orthopedics, cardiology, and oncology [19].

In neurology, MRI plays a critical role in diagnosing conditions such as multiple sclerosis, brain tumors, strokes, and neurodegenerative disorders like Alzheimer's disease. The high contrast resolution of MRI allows healthcare professionals to visualize various brain structures and detect abnormalities that may not be visible in other imaging modalities [19].

In orthopedics, MRI is invaluable for assessing soft tissue injuries, such as ligament tears in the knee or shoulder and cartilage damage in joints. The ability to distinguish between different types of tissues aids in crafting accurate treatment plans [20].

In cardiology, advanced MRI techniques like cardiac MRI enable functional analysis of the heart, assessing myocardial viability, blood flow, and structural anomalies. Additionally, MRI can visualize tumors, offering detailed insights into their size, shape, and extent [21].

The field of MRI is constantly evolving, with innovations aimed at enhancing image quality, reducing scan times, and expanding clinical applications. Techniques such as functional MRI (fMRI) assess brain activity by measuring changes in blood flow, while diffusion-weighted imaging (DWI) provides insights into the movement of water molecules, assisting in the detection of strokes and tumors [21].

Moreover, artificial intelligence (AI) is beginning to play a transformative role in MRI by automating image interpretation, improving diagnostic accuracy, and enhancing workflow efficiency. The integration of AI can enable earlier disease detection and patient management while addressing the increasing demand for imaging services [22].

### Comparative Efficacy of MRI vs. Mammography:

Mammography, a form of radiographic imaging, is the standard screening tool for breast cancer. It uses low-dose X-rays to create detailed images of the breast tissue, allowing for the detection of masses, calcifications, and architectural distortions that may indicate the presence of malignancy. The American Cancer Society recommends that women begin annual mammography screening at age 40, although this can vary based on individual risk factors [22].

The efficacy of mammography in breast cancer detection has been well-documented. Numerous studies have shown that regular screening can reduce breast cancer mortality by approximately 20-30%. The sensitivity of mammography—that is, its ability to correctly identify those with the disease—ranges from 75% to 90%.

However, its sensitivity can be influenced by factors such as breast density and age. Women with dense breast tissue may have lower detection rates due to the masking effect of dense tissue on mammograms, leading to undetected tumors [23].

Magnetic resonance imaging (MRI), on the other hand, utilizes powerful magnets and radio waves to produce high-resolution images of soft tissue structures within the body. In breast imaging, MRI is increasingly recognized for its superior capability to detect cancers, particularly in high-risk populations or in women with dense breast tissue. The sensitivity of MRI in breast cancer detection is significantly higher than that of mammography, often exceeding 90%. This enhanced sensitivity makes MRI an excellent tool for identifying small tumors and evaluating their extent, especially in cases of newly diagnosed cancer [23].

While MRI is an effective diagnostic tool, its role in breast cancer screening is more nuanced. The use of MRI is primarily recommended for women at high risk for breast cancer—those with BRCA1 or BRCA2 gene mutations, a strong family history of breast cancer, or other significant risk factors. The American Cancer Society recommends annual MRI screenings in combination with mammography for these high-risk patients [24].

#### Comparative Efficacy in Detection

When comparing the efficacy of MRI and mammography, several factors must be considered, including sensitivity, specificity, and overall effectiveness in different populations [25].

1. **Sensitivity and Specificity:** MRI has a higher sensitivity for breast cancer detection than mammography, particularly in cases involving dense breast tissue. Studies have suggested that MRI can detect up to 25% more cancers than mammography in high-risk women. However, while MRI is more sensitive, its specificity—defined as the ability to correctly identify those without the disease—can be lower, leading to a higher rate of false-positive results. In contrast, mammography tends to have a higher specificity, resulting in fewer false alarms, but it may miss cancerous lesions, especially in dense breasts [26].

2. **Stage at Diagnosis:** Research indicates that MRI has the potential to identify breast cancers at an earlier stage compared to mammography. Early detection is critical, as smaller tumors generally have better prognoses and respond more favorably to treatment. Consequently, MRI may play a vital role in identifying tumors that are otherwise undetectable via mammography [27].

3. **Population-based Considerations:** The comparative efficacy of MRI and mammography can vary across different populations. For instance, in women with a history of breast cancer or familial predisposition, MRI may be deemed more beneficial. Conversely, population-wide screening programs often lean toward mammography as a cost-effective and systematic approach for detecting breast cancer in asymptomatic women [28].

#### Cost-effectiveness and Accessibility

Cost and accessibility also play crucial roles in the deployment of MRI versus

mammography for breast cancer screening. Mammography is generally more cost-effective and widely available compared to MRI, making it the preferred option for routine screening in the general population. The expense associated with MRI scans is significantly higher, and access may be limited, especially in rural or underserved areas. Consequently, while MRI demonstrates superior efficacy in certain scenarios, the associated costs and availability challenges may restrict its use in general screening programs [29].

The integration of MRI and mammography may offer a balanced approach to breast cancer detection, maximizing the strengths of both modalities. In high-risk groups, a complementary strategy involving both imaging techniques can enhance diagnostic accuracy. For instance, utilizing MRI as an adjunct to mammography can improve the detection rates of breast tumors, allowing for more comprehensive evaluation and management of breast cancer risk [30].

Furthermore, the development of advanced imaging technologies, such as digital mammography and MRI-guided interventions, continues to evolve, potentially improving the efficacy and applicability of both modalities. Emerging technologies, including contrast-enhanced mammography and functional MRI, may further refine the landscape of breast cancer diagnostics [30].

#### MRI Indications for Early-Stage Breast Cancer Screening:

Magnetic Resonance Imaging (MRI) has emerged as a critical tool in the realm of medical diagnostics, particularly in the field of oncology. Breast cancer, a leading cause of cancer-related morbidity and mortality among women, necessitates thorough and precise screening methodologies. While traditional modalities such as mammography and ultrasound have historically dominated breast cancer screening, the utilization of MRI has surged, particularly for early-stage breast cancer detection [31].

MRI utilizes strong magnetic fields and radio waves to generate detailed images of the breast tissue. Compared to traditional mammograms, MRI is highly sensitive and can detect abnormalities that other imaging techniques may overlook, particularly in denser breast tissues [31]. With an increasing understanding of breast cancer genetics, risk factors, and patterns of metastasis, MRI has been integrated into screening protocols, especially for women presenting with certain risk factors or abnormal findings in preliminary screening tests [31].

#### Indications for MRI Screening

1. **High-Risk Populations:** The most significant indication for MRI screening is for women classified as having a high risk of developing breast cancer. This includes individuals with a family history of breast cancer, especially first-degree relatives, those with BRCA1 and BRCA2 gene mutations, and individuals with a history of thoracic irradiation before the age of 30. The American College of Radiology (ACR) and the Radiological Society of North America (RSNA) recommend annual MRI screening for these high-risk groups, stating that the sensitivity of MRI can be as high as 97% [32].
2. **Dense Breast Tissue:** Women with dense breast tissue, as determined

through mammography, may benefit significantly from adding MRI to their screening regimen. Dense breast tissue can obscure tumors on mammograms, leading to a higher rate of false-negative results. Studies have shown that MRI can detect significant numbers of invasive cancers in women with dense breasts that were not visible via mammography. This is particularly important as dense breast tissue is commonly found in premenopausal women [32].

3. **Abnormal Mammogram Findings:** For women who receive inconclusive or suspicious results from mammograms, MRI can be employed as a supplementary tool for further evaluation. This includes patients who exhibit microcalcifications or architectural distortions that require further characterization. MRI can provide a more comprehensive view of the breast tissue and help differentiate between benign and malignant lesions, guiding subsequent management or biopsies [33].

4. **Assessment of Disease Extent:** For women diagnosed with breast cancer, MRI is an essential tool in evaluating the extent of the disease. Preoperative MRI can help determine the size and location of tumors, assess multifocality, or identify contralateral disease that may not have been evident on mammograms. This information is invaluable for surgical planning and for selecting appropriate treatment strategies [34].

5. **Monitoring Response to Therapy:** In cases where patients undergo neoadjuvant chemotherapy (chemotherapy administered before surgical intervention), MRI can be useful for assessing how well the tumor responds to the treatment. Changes in tumor size and morphology can be observed, thereby influencing the timing of surgery and any further therapeutic approaches [35].

6. **Historical Follow-Up:** For individuals who have previously undergone treatment for breast cancer, routine MRI screenings can serve as a tool for surveillance to monitor for the recurrence of cancer. This is particularly relevant for patients who have undergone breast conservation surgery or have a history of high-risk lesions [36].

#### Advantages of MRI Screening

The integration of MRI into breast cancer screening protocols brings several advantages. Its high sensitivity to small tumors, the ability to visualize both in situ and invasive lesions, and its utility in evaluating the full extent of the disease contribute to a more accurate diagnosis. Furthermore, MRI does not involve ionizing radiation, making it a safer alternative for women who require multiple screenings over their lifetime [37].

Despite its notable advantages, there are challenges associated with MRI screening in breast cancer. The primary drawback is the high false-positive rate, which can lead to unnecessary biopsies and procedures, increased anxiety, and additional healthcare costs. Moreover, MRI is not universally accessible, and the costly nature of the procedure may limit its use to specialized centers. Additionally, the interpretation of MRI scans requires skilled radiologists with expertise in breast imaging, underscoring the necessity for appropriate training and standardized protocols [38].

### Advantages of MRI in Characterizing Breast Lesions:

Magnetic Resonance Imaging (MRI) has become an invaluable tool in the diagnosis and management of breast lesions, offering numerous advantages over conventional imaging modalities such as mammography and ultrasound. With its unique ability to provide high-resolution images of soft tissues, MRI has changed the landscape of breast imaging, enabling more accurate characterization of lesions [39].

One of the significant advantages of MRI is its ability to produce detailed images of breast tissue, allowing for a comprehensive assessment of both benign and malignant lesions. MRI utilizes a strong magnetic field and radiofrequency pulses to generate images without the use of ionizing radiation, making it a safer alternative, particularly for young women and those at high risk of breast cancer. The high spatial resolution and excellent soft tissue contrast of MRI provide superior differentiation of various tissues, which is crucial for accurately identifying and characterizing lesions [40].

Additionally, MRI's capability to acquire images in multiple planes (axial, sagittal, and coronal) allows for a three-dimensional perspective of breast anatomy and any lesions present. This multidimensional imaging aids in the assessment of lesion size, shape, and extent, which are critical factors in determining the most appropriate treatment options. The use of contrast agents further enhances visualization, as dynamic contrast-enhanced MRI (DCE-MRI) can evaluate perfusion characteristics of breast lesions, helping to distinguish between malignant and benign entities based on their vascularity [40].

Moreover, MRI is known for its high sensitivity in detecting breast cancer, with reported sensitivity rates ranging from 90% to 95%. Its specificity, however, tends to be lower, leading to concerns about overdiagnosis and unnecessary biopsies. Despite this, the ability of MRI to detect additional malignancies that are not identified by other imaging modalities helps reduce the risk of incomplete assessments and ensures comprehensive surgical planning [41].

The utilization of MRI in high-risk populations, such as women with BRCA1 and BRCA2 mutations, further exemplifies its diagnostic advantages. For these individuals, regular MRI screening can aid in the early identification of malignancies, providing a critical lifeline in managing their elevated cancer risk [42].

In addition to improving diagnostic accuracy, MRI plays a significant role in tailoring personalized treatment plans for breast cancer patients. Once a malignancy is diagnosed, MRI can provide key information regarding tumor size, multifocality, and local staging. This data is essential for surgical planning, particularly when considering breast-conserving surgery versus mastectomy. MRI also assists in evaluating the response to neoadjuvant chemotherapy, allowing for real-time assessment of treatment efficacy and subsequent adjustments to therapeutic regimens [43].

Furthermore, MRI's ability to identify occult lesions can significantly influence the decision-making process in treatment planning. For instance, if MRI reveals additional malignancies, oncologists can employ a more comprehensive approach, ensuring that all cancerous sites are addressed during surgery. Additionally, MRI can

be instrumental in radiation therapy planning, helping to delineate tumor boundaries and ensure accurate targeting while sparing healthy tissue [44].

In cases where patients experience complications or recurrence, MRI serves as a vital tool in monitoring post-treatment outcomes. The imaging modality aids in differentiating between post-treatment changes (such as scar tissue) and recurrent disease, thereby guiding further management decisions [45].

While MRI offers substantial advantages in characterizing breast lesions, it is essential to acknowledge its limitations and the need for judicious use. The high cost of MRI and limited availability in some regions may pose challenges for widespread implementation. Additionally, the relatively high false-positive rates associated with MRI can lead to increased anxiety for patients and unnecessary invasive procedures. Therefore, a multidisciplinary approach that combines MRI findings with clinical and pathological data is essential to optimize patient outcomes [46].

Furthermore, advancements in MRI technology, such as the development of abbreviated MRI protocols, have the potential to enhance accessibility and reduce costs. These innovations aim to streamline the imaging process while maintaining diagnostic efficacy, thereby broadening the scope of MRI's application in breast healthcare [47].

#### Challenges and Limitations of MRI in Breast Cancer Diagnosis:

Magnetic Resonance Imaging (MRI) has increasingly become a critical tool in the diagnosis, staging, and treatment planning of breast cancer. Its ability to provide high-resolution images of soft tissues makes it particularly useful in differentiating between benign and malignant lesions, assessing tumor size, and detecting multifocal or multifocal disease that may not be visible on mammograms or ultrasounds. Despite its advantages, the use of MRI in breast cancer diagnosis is not without challenges and limitations [48].

One of the primary challenges of MRI in breast cancer diagnosis is its accessibility. MRI machines are expensive to procure, maintain, and operate, resulting in significant financial investments for healthcare facilities. This financial burden can lead to limited access in certain communities, especially in rural or underserved areas where healthcare resources are scarce. Moreover, the cost of MRI scans can be a barrier for patients without comprehensive insurance coverage, leading to disparities in access to this diagnostic tool [49].

In addition to financial concerns, the availability of MRI machines can vary significantly across regions. Some hospitals may have limited MRI capacity, resulting in long wait times for appointments. Such delays can prolong the diagnostic process, which is particularly concerning in breast cancer cases where early detection is critical for optimal treatment outcomes. Therefore, while MRI holds great promise for enhancing breast cancer diagnosis, accessibility remains a formidable challenge [50].

Patient-related factors also pose substantial limitations to the effective use of MRI in diagnosing breast cancer. One significant issue is claustrophobia: many patients experience anxiety or fear when placed inside the MRI machine due to its confined

space. This discomfort can deter patients from undergoing MRI scans, particularly as part of routine screening or follow-up evaluations. Appropriately managing this fear often requires additional resources, including psychological support or the use of sedation, which may complicate scheduling and increase operational costs [51].

Moreover, patient characteristics such as body habitus can affect the quality of MRI images. Overweight or obese patients may present challenges in obtaining clear images, which can hinder accurate interpretation. Additionally, certain anatomical factors, such as the presence of dense breast tissue, can complicate MRI diagnostics. Dense breasts may obscure lesions and potentially lead to false-negative results. As a consequence, while MRI can be more sensitive than other imaging modalities, it is not infallible, and its effectiveness can vary based on the individual patient's anatomical and physiological characteristics [52].

The diagnostic efficacy of MRI in breast cancer also presents a notable challenge. Although studies have shown that MRI can increase the detection rate of breast cancer, discrepancies in performance exist based on various factors. For instance, the specificity of breast MRI can be relatively low; this means that while MRI is adept at detecting many cases of breast cancer, it may also yield a high rate of false positives. This overdiagnosis can lead to unnecessary biopsies, psychological stress for patients, and increased healthcare costs [53].

False positives arise due to benign lesions that can mimic cancerous changes on MRI. Examples include fibrocystic changes or adenomas, which can lead to an overestimation of the disease's extent and trigger potentially invasive follow-up procedures. As a result, the balance between sensitivity and specificity needs careful consideration when implementing MRI as a diagnostic tool. Clinicians must weigh the potential benefits of enhanced detection against the risks of over-diagnosis and the associated consequences of unnecessary intervention [54].

The interpretation of MRI scans in breast cancer diagnosis is another significant limitation. Reading MRI images requires a high level of expertise and experience due to the complexity of the breast's anatomical structures and the varied presentations of tumors. Radiologists must distinguish between malignant and benign abnormalities while considering the overlapping characteristics of various lesions. The lack of standardized protocols can contribute to variability in interpretation among practitioners, potentially leading to inconsistent diagnoses [55].

Furthermore, advancements in imaging technology introduce complexities that can further complicate interpretation. New techniques, such as dynamic contrast-enhanced MRI and diffusion-weighted imaging, have the potential to improve diagnostic accuracy but also require additional training and expertise. The extent of radiologist training and experience can significantly influence diagnostic outcomes, underscoring the need for continued education and standardized guidelines in breast MRI interpretation [56].

**Future Directions and Innovations in MRI Technology for Breast Cancer:**

Magnetic Resonance Imaging (MRI) has become an indispensable tool in the diagnosis and management of breast cancer, playing a critical role in detection, characterizing tumor pathology, guiding surgery, and monitoring response to

therapy. As research progresses and technological innovations emerge, the MRI landscape for breast cancer continues to evolve and improve [56].

The cornerstone of future MRI innovations lies in the advancement of imaging techniques. One significant area of development is the integration of high-field MRI technology, particularly with magnets of 7 Tesla or higher. High-field MRI systems provide enhanced spatial and contrast resolution, resulting in improved visualization of small lesions and intricate anatomical details. By detecting subtler changes in breast tissue, these advanced systems can potentially identify early-stage cancers that conventional low-field MRI systems might miss [57].

Moreover, the introduction of novel imaging sequences such as diffusion-weighted imaging (DWI) and magnetic resonance spectroscopy (MRS) is transforming breast cancer MRI. DWI provides information about the cellularity of tissues; higher cellularity often corresponds to malignancy. Employing DWI alongside traditional MRI sequences can enhance tumor characterization, helping differentiate between benign and malignant lesions. MRS, on the other hand, goes a step further by analyzing the chemical composition of tissues, offering insights into metabolic changes associated with tumor growth. Collectively, these techniques refine the diagnostic accuracy of MRI, allowing for more informed clinical decisions [58].

Artificial Intelligence (AI) is redefining many areas of healthcare, and MRI interpretation is no exception. The incorporation of AI algorithms and machine learning into MRI technology has the potential to revolutionize breast cancer diagnosis. AI-powered tools can analyze imaging data more rapidly than traditional methods, providing radiologists with decision support to identify tumors, assess their characteristics, and predict clinical outcomes [59].

Deep learning models trained on large datasets can learn to recognize patterns that distinguish between benign and malignant lesions with remarkable precision. Such tools reduce variability in image interpretation, increase the efficiency of radiological workflows, and may ultimately lead to earlier diagnosis. Additionally, AI can assist in optimizing imaging protocols, ensuring that patients receive the most appropriate sequences for their specific breast cancer risk profiles [60].

Another area of innovation in MRI for breast cancer involves the development of advanced contrast agents. Traditional gadolinium-based contrast agents have been instrumental in enhancing the visibility of tumors, but their limitations regarding patient safety and renal toxicity have raised concerns. Researchers are exploring alternative agents, including those that target specific tumor markers or utilize nanotechnology to deliver contrast at the cellular level [60].

Furthermore, innovative imaging techniques such as dynamic contrast-enhanced MRI (DCE-MRI) are evolving to incorporate these new agents. This technique involves the sequential acquisition of images during the injection of contrast material and allows for the assessment of tumor perfusion and vascular permeability. Enhanced understanding of tumor biology through these advanced imaging techniques can aid in tailoring individualized treatment plans and monitoring therapeutic response [61].

The future of MRI in breast cancer also lies in integrated imaging approaches that combine MRI with other modalities, such as positron emission tomography (PET) and ultrasound. Hybrid imaging systems, like PET/MRI, leverage the strengths of both modalities to provide comprehensive information about a tumor's metabolic activity and its anatomical features. This multimodal approach can improve diagnostic accuracy and offer a more holistic view of tumor behavior, facilitating better treatment decisions [62].

In addition, the integration of MRI with other breast imaging modalities can lead to improved screening programs. For example, employing MRI as a supplemental tool in high-risk populations or implementing it in combination with mammography could enhance early detection rates. As the understanding of breast cancer genetics and risk factors evolves, tailored screening strategies that incorporate advanced imaging techniques can significantly improve patient outcomes [63].

As MRI technology advances, a critical future direction is the emphasis on patient-centric innovations. The current imaging experience can provoke anxiety, and there is an ongoing need to improve patient comfort during MRI scans. Technological advancements, such as shorter scan times facilitated by faster imaging sequences, and patient-friendly designs for MRI machines, will contribute to a more positive experience. Furthermore, innovations in sensory comfort, such as sound and visual distraction techniques during scans, can help mitigate patient anxiety [64].

Education and informed consent are also crucial components of patient-centric care. Emerging technologies in virtual reality (VR) may serve a dual purpose, both in patient education about procedures and in providing relaxation techniques during MRI scans. These approaches not only enhance the patient experience but also result in better cooperation, leading to more accurate scans [65].

## **2. Conclusion:**

In conclusion, the use of MRI in the diagnosis of early-stage breast cancer represents a significant advancement in the field of medical imaging. Its high sensitivity and ability to provide detailed anatomical information make it an invaluable tool for detecting tumors that may be missed by conventional mammography, particularly in patients with dense breast tissue or those at higher risk. As research continues to evolve, MRI's role not only in initial diagnosis but also in treatment monitoring and surgical planning is becoming increasingly recognized. However, it is essential to consider the limitations and potential drawbacks, including availability, cost, and the need for skilled interpretation. Ultimately, the integration of MRI into comprehensive breast cancer screening protocols holds the promise of improving early detection rates and tailoring more effective treatment strategies, thereby enhancing patient outcomes and quality of life. Future studies and technological advancements will further clarify and expand the role of MRI in breast cancer diagnosis, paving the way for more personalized and precise healthcare.

## References

- Kuhl CK, Strobel K, Bieling H, et al. Supplemental breast MR imaging screening of women with average risk of breast cancer. *Radiology* 2017; 283(2):361–70.
- Kuhl C, Weigel S, Schrading S, et al. Prospective multicenter cohort study to refine management recommendations for women at elevated familial risk of breast cancer: the EVA trial. *J Clin Oncol* 2010; 28(9):1450–7.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology – Breast Cancer Screening and Diagnosis. Version 1.2019 (May 17, 2019). 2019.
- Bosse K, Monika G, Gossmann A, et al. Supplemental screening ultrasound increases cancer detection yield in BRCA1 and BRCA2 mutation carriers. *Arch Gynecol Obstet* 2014;289(3):663–70.
- Riedl CC, Nikolaus L, Bernhart C, et al. Triple-modality screening trial for familial breast cancer underlines the importance of magnetic resonance imaging and questions the role of mammography and ultrasound regardless of patient mutation status, age, and breast density. *J Clin Oncol* 2015; 33(10):1128–35.
- Vreemann S, Gubern-Mérida A, Schlooz-Vries MS, et al. Influence of risk category and screening round on the performance of an MR imaging and mammography screening program in carriers of the BRCA mutation and other women at increased risk. *Radiology* 2018;286(2):443–51.
- Mann RM, Nariya C, Moy L. Breast MRI: state of the art. *Radiology* 2019;293(3):520–36.
- Warner E, Kimberley H, Causer P, et al. Prospective study of breast cancer incidence in women with a BRCA1 or BRCA2 mutation under surveillance with and without magnetic resonance imaging. *J Clin Oncol* 2011;(29):1664–9.
- Antoniou A, Pharoah PDP, Narod S, et al. Average risks of breast and ovarian cancer associated with BRCA1 or BRCA2 mutations detected in case series unselected for family history: A combined analysis of 22 studies. *Am J Hum Genet* 2003;72(5):1117–30.
- Sardanelli F, Podo F, Santoro F, et al. Multicenter surveillance of women at high genetic breast cancer risk using mammography, ultrasonography, and contrast-enhanced magnetic resonance imaging (the High Breast Cancer Risk Italian I Study): Final results. *Invest Radiol* 2011;(46):94–105.
- Kriege M, Brekelmans CTM, Boetes C, et al. Differences between first and subsequent rounds of the MRISC breast cancer screening program for women with a familial or genetic predisposition. *Cancer* 2006;106(11):2318–26.
- Houssami N. Overdiagnosis of breast cancer in population screening: does it make breast screening worthless? *Cancer Biol Med* 2017;14(1):1–8.
- Chiarelli AM, Blackmore KM, Muradali D, et al. Performance measures of magnetic resonance imaging plus mammography in the high risk Ontario Breast Screening Program. *J Natl Cancer Inst* 2020; 112(2):136–44.
- Mann RM, Balleyguier C, Baltzer PA, et al. Breast MRI: EUSOBI recommendations for women’s information. *Eur Radiol* 2015;25(12):3669–78.
- National Comprehensive Cancer Network (NCCN) Clinical Practice Guidelines in Oncology - Genetic/Familial High-Risk Assessment: Breast, Ovarian, and Pancreatic. Version 1.2020 (December 4, 2019). 2020.
- Rijnsburger AJ, Inge-Marie O, Kaas R, et al. BRCA1-associated breast cancers present differently from BRCA2-associated and familial cases: Long-term follow-up of Dutch MRISC screening study. *J Clin Oncol* 2010;28(36):5265–73.
- Saslow D, Boetes C, Burke W, et al. American Cancer Society guidelines for breast screening with MRI as an adjunct to mammography. *CA Cancer J Clin* 2007;57(2):75–89.
- van Zelst JCM, Mus RDM, Woldringh G, et al. Surveillance of women with the BRCA1 or BRCA2 mutation by using biannual automated breast US, MR imaging, and mammography. *Radiology* 2017; 285(2):376–88.
- ACOG (American College of Obstetricians and Gynecologists): Committee on practice

- bulletins - Gynecology, Committee on genetics, Society of Gynecologic Oncology. Practice Bulletin No 182: Hereditary Breast and Ovarian Cancer Syndrome. *Obstet Gynecol* 2017;130(3):e110–26.
- Monticciolo DL, Newell MS, Moy L, et al. Breast cancer screening in women at higher-than-average risk: recommendations from the ACR. *J Am Coll Radiol* 2018;15(3 Pt A):408–14.
- Easton DF, Pharoah PDP, Antoniou AC, et al. Gene-panel sequencing and the prediction of breast-cancer risk. *N Engl J Med* 2015;372(23):2243–57.
- Wernli KJ, Ichikawa L, Kerlikowske K, et al. Surveillance breast MRI and mammography: Comparison in women with a personal history of breast cancer. *Radiology* 2019;292(2):311–8.
- Siegel RL, Miller KD, Jemal A. Cancer statistics, 2020. *CA Cancer J Clin* 2020;70(1):7–30.
- Couch FJ, Hermela S, Hu C, et al. Associations between cancer predisposition testing panel genes and breast cancer. *JAMA Oncol* 2017;3(9):1190–6.
- Hartmann LC, Degnim AC, Santen RJ, et al. Atypical hyperplasia of the breast — risk assessment and management options. *N Engl J Med* 2015;372(1):78–89.
- Houssami N, Abraham LA, Onega T, et al. Accuracy of screening mammography in women with a history of lobular carcinoma in situ or atypical hyperplasia of the breast. *Breast Cancer Res Treat* 2014;145(3):765–73.
- Bakker MF, de Lange SV, Pijnappel RM, et al. Supplemental MRI screening for women with extremely dense breast tissue. *N Engl J Med* 2019;381(22):2091–102.
- Houssami N, et al. Current status of supplemental imaging with MRI for the early detection of breast cancer. *Breast* 2022;63:198–204.
- Comstock CE, Gatsonis C, Newstead GM, et al. Comparison of abbreviated breast MRI vs Digital Breast Tomosynthesis for breast cancer detection among women with dense breasts undergoing screening. *JAMA* 2020;323(8):746–56.
- Beattie MS, Blumenthal E, Creasman J, et al. Abstract P2-02-02: uptake and predictors of screening breast MRI in high risk women. *Cancer Res* 2010;70(24 supplement).
- Lowry KP, Rebecca Yates C, Miglioretti DL, et al. Screening performance of digital breast tomosynthesis vs digital mammography in community practice by patient age, screening round, and breast density. *JAMA Netw Open* 2020;3(7):e2011792.
- Punglia RS, Hassett MJ. Using lifetime risk estimates to recommend magnetic resonance imaging screening for breast cancer survivors. *J Clin Oncol* 2010;28(27):4108–10.
- Rafferty EA, Durand MA, Conant EF, et al. Breast cancer screening using tomosynthesis and digital mammography in dense and nondense breasts. *JAMA* 2016;315:1784–6.
- Miles R, Wan F, Onega TL, et al. Underutilization of supplemental magnetic resonance imaging screening among patients at high breast cancer risk. *J Womens Health (Larchmt)* 2018;27(6):748–54.
- Margolin S, Hemming J, Rutqvist LE, et al. Family history, and impact on clinical presentation and prognosis, in a population-based breast cancer cohort from the Stockholm County. *Fam Cancer* 2006;2006(5):4.
- Nathan PC, Kirsten Kimberlie N, Mahoney MC, et al. Screening and surveillance for second malignant neoplasms in adult survivors of childhood cancer: a report from the childhood cancer survivor study. *Ann Intern Med* 2010;153(7):442–51.
- Tieu MT, Cigsar C, Ahmed S, et al. Breast cancer detection among young survivors of pediatric Hodgkin lymphoma with screening magnetic resonance imaging. *Cancer* 2014;120(16):2507–13.
- Lee JM, Buist DSM, Houssami N, et al. Five-year risk of interval-invasive second breast cancer. *J Natl Cancer Inst* 2015;107(7):dju109.
- FDA (Food and Drug Administration) - Proposed MQSA updates including requirement of breast density reporting. 2019.
- Lakhani SR, Jacquemier J, Sloane JP, et al. Multifactorial analysis of differences between sporadic breast cancers and cancers involving BRCA1 and BRCA2 mutations. *J Natl*

- Turki Khulaif Alanazi, Abdullah Naffaa Alsafari, Abdulrahman Abdullah Alsudays, Abdullah Hulayyil Saad Alenazi, Mohammed Maashi Q Alanazi, Ahmed Majid Alzahrani, Mohammad Khulaife Alabdali, Naif Salem Almouwallad, Faris Owais Alharbi  
Cancer Inst 1998;90(15):1138–45.
- Mumtaz H, Hall-Craggs MA, Davidson T, Walmsley K, Thurell W, Kissin MW, Taylor I. Staging of symptomatic primary breast cancer with MR imaging. *AJR Am J Roentgenol.* 1997;169:417–424.
- Hlinka M, Klinka K, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. *Ann Surg Oncol.* 2003;10:381–388.
- Orel SG, Schnall MD, LiVolsi VA, Troupin RH. Suspicious breast lesions: MR imaging with radiologic-pathologic correlation. *Radiology.* 1994;190:485–493.
- Boetes C, Strijk SP, Holland R, Barentsz JO, Van Der Sluis RF, Ruijs JH. False-negative MR imaging of malignant breast tumors. *Eur Radiol.* 1997;7:1231–1234.
- Peters NH, Borel Rinkes IH, Zuihthoff NP, Mali WP, Moons KG, Peeters PH. Meta-analysis of MR imaging in the diagnosis of breast lesions. *Radiology.* 2008;246:116–124.
- Hlawatsch A, Teifke A, Schmidt M, Thelen M. Preoperative assessment of breast cancer: sonography versus MR imaging. *AJR Am J Roentgenol.* 2002;179:1493–1501.
- Butler RS, Venta LA, Wiley EL, Ellis RL, Dempsey PJ, Rubin E. Sonographic evaluation of infiltrating lobular carcinoma. *AJR Am J Roentgenol.* 1999;172:325–330.
- Hwang ES, Kinkel K, Esserman LJ, Lu Y, Weidner N, Hylton NM. Magnetic resonance imaging in patients diagnosed with ductal carcinoma-in-situ: value in the diagnosis of residual disease, occult invasion, and multicentricity. *Ann Surg Oncol.* 2003;10:381–388.
- Kriege M, Brekelmans CT, Boetes C, Besnard PE, Zonderland HM, Obdeijn IM, Manoliu RA, Kok T, Peterse H, Tilanus-Linthorst MM, et al. Efficacy of MRI and mammography for breast-cancer screening in women with a familial or genetic predisposition. *N Engl J Med.* 2004;351:427–437.
- Chapellier C, Balu-Maestro C, Bleuse A, Ettore F, Bruneton JN. Ultrasonography of invasive lobular carcinoma of the breast: sonographic patterns and diagnostic value: report of 102 cases. *Clin Imaging.* 2004;24:333–336.
- Orel SG, Schnall MD. MR imaging of the breast for the detection, diagnosis, and staging of breast cancer. *Radiology.* 2001;220:13–30.
- Samuels JR, Haffty BG, Lee CH, Fischer DB. Breast conservation therapy in patients with mammographically undetected breast cancer. *Radiology.* 1992;185:425–427.
- Howlader N, Noone AM, Krapcho M, Garshell J, Neyman N, Altekruse SF, Kosary CL, Yu M, Ruhl J, Tatalovich Z, Cho H, Mariotto A, Lewis DR, Chen HS, Feuer EJ, Cronin KA. Previous Version: SEER Cancer Statistics Review, 1975-2010. 2013.
- Kuhl CK, Schrading S, Leutner CC, Morakkabati-Spitz N, Wardelmann E, Fimmers R, Kuhn W, Schild HH. Mammography, breast ultrasound, and magnetic resonance imaging for surveillance of women at high familial risk for breast cancer. *J Clin Oncol.* 2005;23:8469–8476.
- Berg WA, Gutierrez L, NessAiver MS, Carter WB, Bhargavan M, Lewis RS, Ioffe OB. Diagnostic accuracy of mammography, clinical examination, US, and MR imaging in preoperative assessment of breast cancer. *Radiology.* 2004;233:830–849.
- Leach MO, Boggis CR, Dixon AK, Easton DF, Eeles RA, Evans DG, Gilbert FJ, Griebisch I, Hoff RJ, Kessar P, et al. Screening with magnetic resonance imaging and mammography of a UK population at
- Kim SH, Cha ES, Park CS, Kang BJ, Whang IY, Lee AW, Song BJ, Park J. Imaging features of invasive lobular carcinoma: comparison with invasive ductal carcinoma. *Jpn J Radiol.* 2011;29:475–482.
- Teller P, Kramer RK. Management of the asymptomatic BRCA mutation carrier. *Appl Clin Genet.* 2010;3:121–131.
- Brem RF, Hoffmeister JW, Rapelyea JA, Zisman G, Mohtashemi K, Jindal G, Disimio MP, Rogers SK. Impact of breast density on computer-aided detection for breast cancer. *AJR Am J Roentgenol.* 2005;184:439–444.

- Sardanelli F, Giuseppetti GM, Panizza P, Bazzocchi M, Fausto A, Simonetti G, Lattanzio V, Del Maschio A. Sensitivity of MRI versus mammography for detecting foci of multifocal, multicentric breast cancer in fatty and dense breasts using the whole-breast pathologic examination as a gold standard. *AJR Am J Roentgenol.* 2004;183:1149–1157.
- Park CS, Jung NY, Kim K, Jung HS, Sohn KM, Oh SJ. Detection of breast cancer in asymptomatic and symptomatic groups using computer-aided detection with full-field digital mammography. *J Breast Cancer.* 2013;16:322–328.
- Elkhuizen PH, van de Vijver MJ, Hermans J, Zonderland HM, van de Velde CJ, Leer JW. Local recurrence after breast-conserving therapy for invasive breast cancer: high incidence in young patients and association with poor survival. *Int J Radiat Oncol Biol Phys.* 1998;40:859–867.
- Peters NH, van Esser S, van den Bosch MA, Storm RK, Plaisier PW, van Dalen T, Diepstraten SC, Weits T, Westenend PJ, Stapper G, et al. Preoperative MRI and surgical management in patients with nonpalpable breast cancer: the MONET - randomised controlled trial. *Eur J Cancer.* 2011;47:879–886.
- Kolb TM, Lichy J, Newhouse JH. Comparison of the performance of screening mammography, physical examination, and breast US and evaluation of factors that influence them: an analysis of 27,825 patient evaluations. *Radiology.* 2002;225:165–175.
- Mann RM, Kuhl CK, Kinkel K, Boetes C. Breast MRI: guidelines from the European Society of Breast Imaging. *Eur Radiol.* 2008;18:1307–1318.